Trial reportOphthalmology2016
Five-Year Safety and Performance Results from the Argus II Retinal Prosthesis System Clinical Trial.
Trial report in Ophthalmology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05914233 (Revolutionary Non-Invasive Ultrasound Technology for Vision Restoration in Age-Related Macular Degeneration), which is not on this map. Cited by 176 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Revolutionary Non-Invasive Ultrasound Technology for Vision Restoration in Age-Related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP) Patients
Who cites it
176 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Retinal Implantation of Electronic Vision Prostheses to Treat Retinitis Pigmentosa: A Systematic Review.Translational vision science & technology · 2021Pooled it
- Interobserver Agreement of Electrode to Retina Distance Measurements in a Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis.Translational vision science & technology · 2022Trial
- A Second-Generation (44-Channel) Suprachoroidal Retinal Prosthesis: Interim Clinical Trial Results.Translational vision science & technology · 2021Trial
- Assessment of the Electronic Retinal Implant Alpha AMS in Restoring Vision to Blind Patients with End-Stage Retinitis Pigmentosa.Ophthalmology · 2018Trial
- Determinants of spatial resolution in retinal prostheses: understanding the gap between geometry and vision.Biomedical engineering letters · 2026Review
- Trends in neuroprosthetic technologies to restore sensations.Biomedical engineering letters · 2026Review
- Seeing anew: Mechanisms, outcomes, and challenges in adapting to restored sight via visual prostheses.Progress in retinal and eye research · 2026Review
- Stress-Based Assessment of Bio-Inspired Phosphene Vision Encoding: Trade-Offs Among Performance, Residual Proxy Safety Burden, and Topology-Based Representation Metrics.Biomimetics (Basel, Switzerland) · 2026Article
- The Association of Primate Veterinarians and the European Primate Veterinarians Position Statement on the Value of Nonhuman Primates in Research.Journal of the American Association for Laboratory Animal Science : JAALAS · 2026Article
- Gamification Enhances User Engagement and Task Performance in Prosthetic Vision Testing.Translational vision science & technology · 2026Article
- Wireless image transfer across opaque cornea: A novel approach to visual rehabilitation.Indian journal of ophthalmology · 2026Article
- Design and Preclinical Validation of an Eyeglass-Coupled Perilimbal Antenna for Retinal Prostheses With a Biocompatible Graft Technique.Translational vision science & technology · 2026Article
- Keeping a PROMise: embedding patient voices in ophthalmic outcomes.The British journal of ophthalmology · 2026Article
- Motion perception with visual prostheses.Progress in biomedical engineering (Bristol, England) · 2026Review
- Bilateral retinal implants for improving visual restoration: a simulated bionic vision study.Medical & biological engineering & computing · 2026Article
- Intraocular Micro-LED Epiretinal Projection for Anterior Segment Blindness: Design and Large-Animal Feasibility Study.Bioengineering (Basel, Switzerland) · 2026Article
- Multi-Level Perception Systems in Fusion of Lifeforms: Classification, Challenges and Future Conceptions.Sensors (Basel, Switzerland) · 2026Review
- Leveraging large scale deep learning models for diagnosis and visual outcome prediction in retinitis pigmentosa.NPJ digital medicine · 2026Article
- Brain-Computer Interfaces for Vision Recovery in Precortical Vision Loss.Eye and brain · 2026Review
- Gamification Enhances User Engagement and Task Performance in Prosthetic Vision Testing.medRxiv : the preprint server for health sciences · 2025Article
116 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Funding
Abstract
purposeThe Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, Sylmar, CA) was developed to restore some vision to patients blind as a result of retinitis pigmentosa (RP) or outer retinal degeneration. A clinical trial was initiated in 2006 to study the long-term safety and efficacy of the Argus II System in patients with bare or no light perception resulting from end-stage RP.
designProspective, multicenter, single-arm clinical trial. Within-patient controls included the nonimplanted fellow eye and patients' native residual vision compared with their vision with the Argus II.
participantsThirty participants in 10 centers in the United States and Europe.
methodsThe worse-seeing eye of blind patients was implanted with the Argus II. Patients wore glasses mounted with a small camera and a video processor that converted images into stimulation patterns sent to the electrode array on the retina.
main outcome measuresThe primary outcome measures were safety (the number, seriousness, and relatedness of adverse events) and visual function, as measured by 3 computer-based, objective tests. Secondary measures included functional vision performance on objectively scored real-world tasks.
resultsTwenty-four of 30 patients remained implanted with functioning Argus II Systems at 5 years after implantation. Only 1 additional serious adverse event was experienced after the 3-year time point. Patients performed significantly better with the Argus II on than off on all visual function tests and functional vision tasks.
conclusionsThe 5-year results of the Argus II trial support the long-term safety profile and benefit of the Argus II System for patients blind as a result of RP. The Argus II is the first and only retinal implant to have market approval in the European Economic Area, the United States, and Canada.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.